Atrial fibrillation (AF) confers a significant risk of stroke or systemic thromboembolism. Oral
anticoagulation is the most effective therapy for AF-related stroke prevention. A decision to …

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. Strokes that occur
as a complication of AF are usually more severe and associated with a higher disability or …

Atrial fibrillation (AF) is a common heart rhythm disturbance; its incidence increases with
age, and it is also an independent risk factor for stroke. Anticoagulation has been proven as …

Abstract Objectives: Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K
antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with …

The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia,
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …

For decades, warfarin has remained the standard oral anticoagulation for stroke prevention
in atrial fibrillation (AF). Three novel oral anticoagulants (NOACs) have been recently …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases risk of
stroke by nearly 5-fold. While warfarin has been employed successfully to reduce the risk of …

Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia associated with an increased
risk of stroke. The role of anticoagulation therapy in the prevention of thrombosis and stroke …

The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …

Increasing use of the new oral anticoagulants (NOACs)–dabigatran, rivaroxaban, and
apixaban–has prompted considerable discussion in the medical community even as …